Evidence map›Paper›PMID 40790213›Full record

ArticleCell communication and signaling : CCS2025

Activation of integrin signaling up-regulates pro-inflammatory cytokines in JAK2-V617F positive hematopoietic cells.

Conny K Baldauf, Corinna Fahldieck, Alexa Angenstein, Sönke Weinert, Mariam Hakobyan, Daniel B Lipka, Tobias R Haage, Vikas Bhuria, Martin Böttcher, Dimitrios Mougiakakos and 2 more

Abstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Impact of CaInternational journal of molecular sciences · 2026
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Conny K BaldaufInstitute for Molecular and Clinical Immunology, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany.
Corinna FahldieckDepartment of Hematology, Oncology and Cell Therapy, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany.
Alexa AngensteinDepartment of Hematology, Oncology and Cell Therapy, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany.
Sönke WeinertUniversity Clinic for Cardiology and Angiology, Otto-von-Guericke University, Medical Faculty, Magdeburg, Germany.
Mariam HakobyanSection of Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Daniel B LipkaSection of Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Tobias R HaageDepartment of Hematology, Oncology and Cell Therapy, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany.
Vikas BhuriaHealthcampus Immunology, Inflammation and Infectiology (GC-I3), Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany.
Martin BöttcherHealthcampus Immunology, Inflammation and Infectiology (GC-I3), Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany.
Dimitrios MougiakakosHealthcampus Immunology, Inflammation and Infectiology (GC-I3), Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany.
Burkhart SchravenInstitute for Molecular and Clinical Immunology, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany.
Thomas FischerHealthcampus Immunology, Inflammation and Infectiology (GC-I3), Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany. thomas.fischer@med.ovgu.de.

Funding

Deutsche Forschungsgemeinschaft (DFG). RTG2408German Research Council (Deutsche Forschungsgemeinschaft (DFG)) 97850925/SFB854/A20German Research Council (Deutsche Forschungsgemeinschaft (DFG)) 97850925/SFB854/B19
6 · The paper itself

Abstract

backgroundThe JAK2-V617F mutation is the most frequent driver mutation in a group of malignant hematopoietic disorders called myeloproliferative neoplasms (MPN). JAK2-V617F is a somatic mutation originating in a hematopoietic stem cell and results in constitutively activated JAK-STAT signaling. High levels of pro-inflammatory cytokines in the blood are a hallmark of MPN patients and are a key factor in the severe clinical symptoms seen in these patients. The molecular mechanisms underlying the up-regulation of inflammatory cytokines in JAK2-V617F mutated hematopoietic cells remain to be elucidated.

methods32D myeloid progenitor cells expressing JAK2-wildtype (WT) and JAK2-V617F, respectively were employed. In addition, primary hematopoietic cells from the JAK2-V617F knock-in MPN mouse model were investigated. Integrin outside-in signaling upon binding of cells to the adhesion molecules VCAM-1/ICAM-1 was characterized by Western blotting of phosphorylated FAK, STAT3, p65, SYK and JNK. Regulation of mRNA and protein expression of IL-1α, IL-1β, IL-6, TNF and CXCL10 was measured by qPCR and ELISA. RNAseq and DNA methylation analysis in primary mouse JAK2-V617F granulocytes was performed. In JAK2-V617F knock-in mice, anti-integrin treatment was applied to evaluate the impact of activated integrin signaling on IL-1 blood levels in vivo.

resultsIntegrin stimulation via the adhesion molecules VCAM-1/ICAM-1 activated integrin outside-in signaling including FAK, SYK, NFκB, and JNK. This induced strong mRNA expression of IL-1α, IL-1β, IL-6, TNF and CXCL10. In 32D cells, the presence of the JAK2-V617F mutation further increased VCAM-1/ICAM-1-induced mRNA and protein levels of IL-1α and IL-1β, and active caspase 1 expression. In primary granulocytes, integrin stimulation resulted in an activated mRNA signature of inflammatory cytokines. Consistent with the mRNA results, adhesion to VCAM-1/ICAM-1 induced an increase in intracellular IL-1α and IL-1β protein levels in 32D cells. However, in primary hematopoietic cells, up-regulation of inflammatory cytokines was not observed at the protein level in vitro, whereas, in vivo, blocking of integrin binding to VCAM-1/ICAM-1 was sufficient to reduce elevated IL-1α levels in the blood of JAK2-V617F mice.

conclusionsWe conclude that integrin stimulation via the adhesion molecules VCAM-1/ICAM-1 activates integrin outside-in signaling, leading to the up-regulation of pro-inflammatory cytokines in both JAK2-mutated and non-mutated mouse hematopoietic cells.

Indexed as

CytokinesHematopoietic Stem CellsIntegrinsJanus Kinase 2Signal TransductionUp-RegulationAnimalsHumansMiceMutationMyeloproliferative DisordersCytokinesIntegrinsJak2 protein, mouseJanus Kinase 2AdhesionICAM-1IL-1αIL-1βInflammationIntegrinsJAK2-V617FMPNPro-inflammatory cytokinesVCAM-1

Identifiers

PMID40790213
PMCPMC12337553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.